A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma-Reference-Cited by-同舟云学术

A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma

Published:2001-10 Issue:4 Volume:122 Page:788-795
ISSN:0022-5223
Container-title:The Journal of Thoracic and Cardiovascular Surgery
language:en
Short-container-title:The Journal of Thoracic and Cardiovascular Surgery

Author:

Rusch Valerie W.,Rosenzweig Kenneth,Venkatraman Ennapadam,Leon Larry,Raben Adam,Harrison Louis,Bains Manjit S.,Downey Robert J.,Ginsberg Robert J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference35 articles.

1. The role of extrapleural pneumonectomy in malignant pleural mesothelioma;Rusch;J Thorac Cardiovasc Surg,1991

2. Surgically debulked malignant pleural mesothelioma: results and prognostic factors;Pass;Ann Surg Oncol,1997

3. Results of treatment of malignant pleural mesothelioma with surgery, brachytherapy, and external beam irradiation [abstract];Mychalczak;Endocurie Hypertherm Oncol,1989

4. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma;Rusch;J Clin Oncol,1994

5. Patterns of failure after trimodality therapy for malignant pleural mesothelioma;Baldini;Ann Thorac Surg,1997

Cited by 444 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma;Thoracic Cancer;2023-07-17

2. Surgical Management of Malignant Pleural Mesothelioma: From the Past to the Future;Mesothelioma - Diagnostics, Treatment and Basic Research;2022-12-21

3. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma;Clinical Cancer Research;2022-12-05

4. Repurposing clofazimine for malignant pleural mesothelioma treatment — In-vitro assessment of efficacy and mechanism of action;Life Sciences;2022-10

5. Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors;Clinical Cancer Research;2022-09-12